Olaparib and durvalumab in patients with germline BRCA-mutated metastatic breast cancer (MEDIOLA): an open-label, multicentre, phase 1/2, basket study

Susan M. Domchek, Sophie Postel‐Vinay, Seock‐Ah Im, +22

The Lancet Oncology

Phase 1/2Breast OncologyOncologyBasket StudyPathology +6

Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer

Charles E. Geyer, Judy E. Garber, Richard D. Gelber, +510

Annals of Oncology

Breast OncologyOverall SurvivalMedicinePathologyGermline Pathogenic Variants +5

Prospective evaluation of the cardiac safety of HER2-targeted therapies in patients with HER2-positive breast cancer and compromised heart function: the SAFE-HEaRt study

Filipa Lynce, Ana Barac, Xue Geng, +17

Breast Cancer Research and Treatment

An open-label, phase II basket study of olaparib and durvalumab (MEDIOLA): Results in germline BRCA -mutated ( gBRCA m) platinum-sensitive relapsed (PSR) ovarian cancer (OC)

Yvette Drew, Maja J.A. de Jonge, Sook Hee Hong, +14

Gynecologic Oncology

Gbrca MMedicineGynecologyPathologyCancer Treatment +4

BEGONIA: Phase 1b/2 study of durvalumab (D) combinations in locally advanced/metastatic triple-negative breast cancer (TNBC)—Initial results from arm 1, d+paclitaxel (P), and arm 6, d+trastuzumab deruxtecan (T-DXd).

Peter Schmid, Seock‐Ah Im, Anne Armstrong, +11

Journal of Clinical Oncology

Poor Clinical OutcomesBreast OncologyImmunologyImmunoeditingPathology +21

Phase II study of olaparib + durvalumab (MEDIOLA): Updated results in germline BRCA-mutated platinum-sensitive relapsed (PSR) ovarian cancer (OC)

Yvette Drew, Bella Kaufman, Susana Banerjee, +15

Annals of Oncology

MedicinePathologyGynecologyPhase Ii StudyCancer Treatment +4

Phase II study of olaparib (O) and durvalumab (D) (MEDIOLA): Updated results in patients (pts) with germline BRCA-mutated (gBRCAm) metastatic breast cancer (MBC)

Susan M. Domchek, S. Postel-Vinay, S.-A. Im, +16

Annals of Oncology

Metastatic Breast CancerBreast OncologyMedicineGynecologyPathology +8

Abstract PD6-11: An open-label, multitumor, phase II basket study of olaparib and durvalumab (MEDIOLA): Results in germline <i>BRCA</i> -mutated (g <i>BRCA</i> m) HER2-negative metastatic breast cancer (MBC)

S. M. Domchek, Sophie Postel‐Vinay, Y-J. Bang, +15

Cancer Research

An open-label, phase II basket study of olaparib and durvalumab (MEDIOLA): Results in patients with relapsed gastric cancer.

Yung‐Jue Bang, Bella Kaufman, Ravit Geva, +11

Journal of Clinical Oncology

Cancer ManagementGastroenterologyPathologyPharmacotherapyOncology +15

Olaparib and durvalumab in patients with relapsed small cell lung cancer (MEDIOLA): An open-label, multicenter, phase 1/2, basket study

Matthew Krebs, Jean‐Pierre Delord, T.R. Jeffry Evans, +13

Lung Cancer